Xiao Xiang, Wu Xuanyu, Li Wenyuan, You Fengming, Guo Jing
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Evidence-Based Traditional Chinese Medicine Center of Sichuan Province, Chengdu, China.
Front Nutr. 2025 Aug 29;12:1644538. doi: 10.3389/fnut.2025.1644538. eCollection 2025.
Lung cancer (LC) is the most common cause of cancer-related death worldwide, while there are limited treatment methods. Resveratrol (RESV), a natural food-derived compound, has attracted attention around the world for its anti-LC effects. However, little is known about the efficacy and safety of RESV for LC.
This study aimed to provide preclinical evidence for the efficacy and safety of RESV for LC, and to find the optimal dose and duration.
studies of RESV against LC, published before 24 July 2024, were retrieved from PubMed, Embase, Web of Science, and Cochrane Library. The CAMARADES checklist was used to assess study quality. Primary outcomes were tumor volume and tumor weight. Secondary outcomes included body weight, lung metastases number, and the apoptotic cell proportion. Statistical analysis was performed using RevMan 5.3 and Stata 16.0. Dose-duration-effect model was conducted to determine the optimal dose and duration, and the toxicology of RESV was predicted through the ProTox 3.0 platform.
A total of 23 studies involving 425 animals were included. The methodological quality of included studies was medium-to-low. RESV significantly reduced tumor volume, tumor weight, and lung metastases number, and increased apoptotic cell proportion, while having no effect on body weight. High heterogeneity was observed, and subgroup analysis suggested that the heterogeneity was partly attributed to the dose of RESV. The optimal dose and duration of RESV were 30-100 mg/kg and 25-28 days, respectively. The median lethal dose of RESV was 1,560 mg/kg.
RESV demonstrated a significant inhibitory effect on LC . However, the lower research quality and high heterogeneity call for more high-quality preclinical studies to be conducted. Before achieving clinical translational research on RESV, the problem of low bioavailability of RESV needs to be solved.
肺癌（LC）是全球癌症相关死亡的最常见原因，而治疗方法有限。白藜芦醇（RESV）是一种天然的食物衍生化合物，其抗肺癌作用已引起全球关注。然而，关于RESV对肺癌的疗效和安全性知之甚少。
本研究旨在为RESV对肺癌的疗效和安全性提供临床前证据，并找到最佳剂量和疗程。
从PubMed、Embase、科学网和Cochrane图书馆检索2024年7月24日前发表的关于RESV抗肺癌的研究。使用CAMARADES清单评估研究质量。主要结局为肿瘤体积和肿瘤重量。次要结局包括体重、肺转移灶数量和凋亡细胞比例。使用RevMan 5.3和Stata 16.0进行统计分析。进行剂量-疗程-效应模型以确定最佳剂量和疗程，并通过ProTox 3.0平台预测RESV的毒理学。
共纳入23项研究，涉及425只动物。纳入研究的方法学质量为中低水平。RESV显著降低了肿瘤体积、肿瘤重量和肺转移灶数量，并增加了凋亡细胞比例，而对体重无影响。观察到高度异质性，亚组分析表明异质性部分归因于RESV的剂量。RESV的最佳剂量和疗程分别为30-100mg/kg和25-28天。RESV的半数致死剂量为1560mg/kg。
RESV对肺癌显示出显著的抑制作用。然而，较低的研究质量和高度异质性需要进行更多高质量的临床前研究。在实现RESV的临床转化研究之前，需要解决RESV生物利用度低的问题。
